1,379 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Shr-A1904 Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (40)
Shr-A1921 For Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (40)
Shr-A2009 For Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (40)
SKB103 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1/2	CC (40)
SKB105 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1/2	CC (40)
skl27969 Cancer	SK Life Science, Inc.	P1/2	CC (40)
snv4818 Cancer	Pikavation Therapeutics, Inc.	P1/2	CC (40)
Solnerstotug Cancer	Sensei Biotherapeutics, Inc.	P1/2	CC (40)
srp1020 Cancer	Shanghai SciBrunch Therapeutics Co., Ltd.	P1/2	CC (40)
Star0602 Cancer	Marengo Therapeutics, Inc.	P1/2	CC (40)
Sti-7349 Cancer	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	P1/2	CC (40)
Stk-012 Cancer	Synthekine	P1/2	CC (40)
Stx-001 Cancer	Strand Therapeutics Inc.	P1/2	CC (40)
syh2051 Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P1/2	CC (40)
sys6002 Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
sys6010 Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
sys6045 Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P1/2	CC (40)
t3011 Cancer	Shanghai Pharmaceuticals Holding Co., Ltd	P1/2	CC (40)
t3p-y058-739 Cancer	T3 Pharmaceuticals AG	P1/2	CC (40)
tfx05-01 Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (40)
Tirelizumab Cancer	LaNova Medicines Limited	P1/2	CC (40)
tj1133 Cancer	TJ Biopharma Co., Ltd.	P1/2	CC (40)
tno155 Cancer	Mirati Therapeutics Inc.	P1	CC (40)
tqb2101 for Cancer	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1/2	CC (40)
Transcon Il-2 Β/Γ Cancer	Ascendis Pharma Oncology Division A/S	P1/2	CC (40)
Transcon Tlr7/8 Agonist Cancer	Ascendis Pharma Oncology Division A/S	P1/2	CC (40)
Trastuzumab Emtansine Cancer	Seoul National University Bundang Hospital	P1/2	CC (40)
tt-702 Cancer	Cancer Research UK	P1/2	CC (40)
Ttx-Mc138 Cancer	TransCode Therapeutics	P1/2	CC (40)
tu2218 Cancer	TiumBio Co., Ltd.	P1/2	CC (40)
Tub-030 Cancer	Tubulis GmbH	P1/2	CC (40)
Tucidinostat Cancer	Chinese PLA General Hospital	P1/2	CC (40)
Tulmimetostat Cancer	Novartis Pharmaceuticals	P1/2	CC (40)
Tyra-300 Cancer	Tyra Biosciences, Inc	P1/2	CC (40)
Urea Cancer	Robert Bok, MD, PhD	P1/2	CC (40)
vib305 for Cancer	Vibrant Sciences Limited	P1/2	CC (40)
Vls-1488 Cancer	Volastra Therapeutics, Inc.	P1/2	CC (40)
Vofatamab Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
Wef-001 Cancer	Auricula Biosciences Inc.	P1/2	CC (40)
wj22096 Cancer	Nanjing Jingao biomidical technology Co. Ltd.	P1/2	CC (40)
wjb001 Cancer	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	P1/2	CC (40)
xnw28012 Cancer	Evopoint Biosciences Inc.	P1/2	CC (40)
xon7 Cancer	Xenothera SAS	P1/2	CC (40)
xtx301 Cancer	Xilio Development, Inc.	P1/2	CC (40)
yl-15293 Cancer	Shanghai YingLi Pharmaceutical Co. Ltd.	P1/2	CC (40)
YL201 for Cancer	MediLink Therapeutics (Suzhou) Co., Ltd.	P1/2	CC (40)
yl242 Cancer	MediLink Therapeutics (Suzhou) Co., Ltd.	P1/2	CC (40)
Zelenectide Pavedotin Cancer	BicycleTx Limited	P1/2	CC (40)
Zggs18 For Cancer	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
Zoldonrasib Cancer	Revolution Medicines, Inc.	P1/2	CC (40)

Showing 701 to 750 of 1,379 assets

PreviousPage 15 of 28Next